Literature DB >> 16506527

MT-103 Micromet/MedImmune.

Eleanor J Cheadle1.   

Abstract

Micromet AG and Medlmmune Inc are developing MT-103, a single-chain bispecific recombinant antibody from Micromet's BiTE (bispecific T-cell engager) product platform that binds both the CD19 antigen and the T-cell receptor (CD3), for the potential treatment of B-cell lymphoma. The company is also investigating the compound for the potential treatment of chronic lymphocytic leukemia and acute lymphoblastic leukemia.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16506527

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN： 1464-8431


  2 in total

1.  Potent and conditional redirected T cell killing of tumor cells using Half DVD-Ig.

Authors:  Philip D Bardwell; Matthew M Staron; Junjian Liu; Qingfeng Tao; Susanne Scesney; Gail Bukofzer; Luis E Rodriguez; Chee-Ho Choi; Jennifer Wang; Qing Chang; Feng Dong; Cherrie Donawho; Jieyi Wang; Christine M Grinnell; Edit Tarcsa; Charles Hutchins; Tariq Ghayur; Jijie Gu
Journal:  Protein Cell       Date:  2017-06-05       Impact factor: 14.870

2.  CD19xCD3 DART protein mediates human B-cell depletion in vivo in humanized BLT mice.

Authors:  Perry Tsai; William O Thayer; Liqin Liu; Guido Silvestri; Jeffrey L Nordstrom; J Victor Garcia
Journal:  Mol Ther Oncolytics       Date:  2016-03-02       Impact factor: 7.200
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.